Synthesis and Distribution of Drugs of Abuse and Related Compounds
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has issued a non-competitive Notice of Intent to modify an existing Single Award Indefinite Delivery, Indefinite Quantity (IDIQ) contract with Research Triangle Institute. The modification will increase the IDIQ maximum by $3,718,289, raising the total from $14,004,330 to $17,722,619. This action aims to ensure the continuation of critical support services for scientific research on substance use and drug dependence, including the synthesis and distribution of controlled drugs and research chemicals. Interested parties may submit capability statements or objections by February 13, 2026.
Scope of Work
The contract, titled "Synthesis and Distribution of Drugs of Abuse and Related Compounds," provides essential services including:
- Producing and distributing labeled and unlabeled drugs of abuse and other research compounds.
- Analyzing, testing, and maintaining the purity of drug supply inventory.
- Replenishing existing drug supply through synthesis or acquisition.
- Identifying, acquiring, storing, and updating the inventory with newly discovered chemical compounds.
- Maintaining the NIDA Drug Inventory Supply Control System (DISCS) database. These services support pre-clinical and clinical trials by providing authentic and pure supplies of controlled drugs and research chemicals.
Contract Details
- Opportunity Type: Special Notice (Non-Competitive, Sole Source Modification)
- Current Contractor: Research Triangle Institute
- Contract Number: 75N95022D00016
- Modification Purpose: Increase IDIQ maximum to continue work, prevent delays, and support increased demand for drug products for clinical trials.
- New IDIQ Maximum: $17,722,619
- Period of Performance: June 9, 2022, to June 8, 2027 (unchanged)
- NAICS Code: 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology))
- PSC: AN11 (Health R&D Services; Health Care Services; Basic Research)
- Set-Aside: None (Sole Source)
- Authority: FAR 6.103-1 (Only one responsible source)
Response Information
This is not a request for competitive proposals. However, interested parties may respond by identifying their interest, submitting capability statements, or objecting to the proposed modification. Responses will be considered to determine if proceeding on a non-competitive basis is appropriate.
- Response Deadline: February 13, 2026, 1:00 p.m. Eastern Daylight Time
- Submission: Electronically to Shaun Rostad (shaun.rostad@nih.gov)
- Requirements: Active SAM.gov registration, Unique Entity Identifier (UEI), Taxpayer Identification Number (TIN), and certification of business size.